10 assets in Primary Brain Neoplasm

Therapeutic assets addressing Primary Brain Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Rvp-001 Primary Brain Neoplasm	Reveal Pharmaceuticals Inc.	P2	B (57)
Entrectinib Primary Brain Neoplasm	Hoffmann-La Roche	P2	CCC (53)
Capecitabine Primary Brain Neoplasm	Northwell Health	P1/2	CCC (48)
Avutometinib Primary Brain Neoplasm	Memorial Sloan Kettering Cancer Center	P1	CC (43)
Cyclophosphamide Primary Brain Neoplasm	Theodore S. Johnson	P1	CC (43)
Definity Primary Brain Neoplasm	Sunnybrook Health Sciences Centre	P1	CC (43)
Etoposide Primary Brain Neoplasm	Theodore S. Johnson	P1	CC (43)
Ibrutinib Primary Brain Neoplasm	Theodore S. Johnson	P1	CC (43)
Indoximod Primary Brain Neoplasm	Theodore S. Johnson	P1	CC (43)
Icp-723 Primary Brain Neoplasm	Beijing InnoCare Pharma Tech Co., Ltd.	P1/2	NR ()